The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients
Open accessAbstract
BACKGROUND: Among trauma patients who survive to reach hospital, exsanguination is a common cause of death. A widely practicable treatment that reduces blood loss after trauma could prevent thousands of premature deaths each year. The CRASH-2 trial aimed to determine the effect of the early administration of tranexamic acid on death and transfusion requirement in bleeding trauma patients. In addition, the effort of tranexamic acid on the risk of vascular occlusive events was assessed. OBJECTIVE: Tranexamic acid (TXA) reduces bleeding in patients undergoing elective surgery. We assessed the effects and cost-effectiveness of the early administration of a short course of TXA on death, vascular occlusive events and the receipt of blood transfusion in trauma patients. DESIGN: Randomised placebo-controlled trial and economic evaluation. Randomisation was balanced by centre, with an allocation sequence based on a block size of eight, generated with a computer random number generator. Both participants and study staff (site investigators and trial co-ordinating centre staff) were masked to treatment allocation. All analyses were by intention to treat. A Markov model was used to assess cost-effectiveness. The health outcome was the number of life-years (LYs) gained. Cost data were obtained from hospitals, the World Health Organization database and UK reference costs. Cost-effectiveness was measured in international dollars ($) per LY. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results to model assumptions. SETTING: Two hundred and seventy-four hospitals in 40 countries. PARTICIPANTS: Adult trauma patients (n = 20,211) with, or at risk of, significant bleeding who were within 8 hours of injury. INTERVENTIONS: Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours) or matching placebo. MAIN OUTCOME MEASURES: The primary outcome was death in hospital within 4 weeks of injury, and was described with the following categories: bleeding, vascular occlusion (myocardial infarction, stroke and pulmonary embolism), multiorgan failure, head injury and other. RESULTS: Patients were allocated to TXA (n = 10,096) and to placebo (n = 10,115), of whom 10,060 and 10,067 patients, respectively, were analysed. All-cause mortality at 28 days was significantly reduced by TXA [1463 patients (14.5%) in the TXA group vs 1613 patients (16.0%) in the placebo group; relative risk (RR) 0.91; 95% confidence interval (CI) 0.85 to 0.97; p = 0.0035]. The risk of death due to bleeding was significantly reduced [489 patients (4.9%) died in the TXA group vs 574 patients (5.7%) in the placebo group; RR 0.85; 95% CI 0.76 to 0.96; p = 0.0077]. We recorded strong evidence that the effect of TXA on death due to bleeding varied according to the time from injury to treatment (test for interaction p < 0.0001). Early treatment (≤ 1 hour from injury) significantly reduced the risk of death due to bleeding [198 out of 3747 patients (5.3%) died in the TXA group vs 286 out of 3704 patients (7.7%) in the placebo group; RR 0.68; 95% CI 0.57 to 0.82; p < 0.0001]. Treatment given between 1 and 3 hours also reduced the risk of death due to bleeding [147 out of 3037 patients (4.8%) died in the TXA group vs 184 out of 2996 patients (6.1%) in the placebo group; RR 0.79; 95% CI 0.64 to 0.97; p = 0.03]. Treatment given after 3 hours seemed to increase the risk of death due to bleeding [144 out of 3272 patients (4.4%) died in the TXA group vs 103 out of 3362 patients (3.1%) in the placebo group; RR 1.44; 95% CI1.12 to 1.84; p = 0.004]. We recorded no evidence that the effect of TXA on death due to bleeding varied by systolic blood pressure, Glasgow Coma Scale score or type of injury. Administering TXA to bleeding trauma patients within 3 hours of injury saved an estimated 755 LYs per 1000 trauma patients in the UK. The cost of giving TXA to 1000 patients was estimated at $30,830. The incremental cost of giving TXA compared with not giving TXA was $48,002. The incremental cost per LY gained of administering TXA was $64. CONCLUSIONS: Early administration of TXA safely reduced the risk of death in bleeding trauma patients and is highly cost-effective. Treatment beyond 3 hours of injury is unlikely to be effective. Future work [the Clinical Randomisation of an Antifibrinolytic in Significant Head injury-3 (CRASH-3) trial] will evaluate the effectiveness and safety of TXA in the treatments of isolated traumatic brain injury (http://crash3.lshtm.ac.uk/). TRIAL REGISTRATION: Current Controlled Trials ISRCTN86750102, ClinicalTrials.gov NCT00375258 and South African Clinical Trial Register DOH-27-0607-1919. FUNDING: The project was funded by the Bupa Foundation, the J P Moulton Charitable Foundation and the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 17, No. 10. See HTA programme website for further project information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
Epidemiology of Trauma Deaths: A Reassessment
Sauaia, A., Moore, F. A., Moore, E. E., Moser, K. S., Brennan, R., Read, R. A., & Pons, P. T. (1995) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-199502000-00006 · Cited by 1,879
(2003) · RePEc: Research Papers in Economics · Cited by 1,844
Macroeconomics and health: investing in health for economic development
Sachs, J. D. (2002) · Revista Panamericana de Salud Pública · doi:10.1590/s1020-49892002000800017 · Cited by 1,830
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Henry, D. A., Carless, P. A., Moxey, A. J., O’Connell, D. L., Stokes, B., Fergusson, D. A., & Ker, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001886.pub4 · Cited by 1,065
Yusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014
The National Institute for Clinical Excellence (NICE)
Rodgers, A.-T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii92 · Cited by 966
The Coagulopathy of Trauma: A Review of Mechanisms
Hess, J. R., Brohi, K., Dutton, R. P., Hauser, C. J., Holcomb, J. B., Kluger, Y., Mackway-Jones, K., Parr, M. J., Rizoli, S. B., Yukioka, T., et al. (2008) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e3181877a9c · Cited by 933
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses
Sun, X., Briel, M., Walter, S. D., & Guyatt, G. H. (2010) · BMJ · doi:10.1136/bmj.c117 · Cited by 808
Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
(2009) · JIBL · doi:10.1515/jibl.2009.12 · Cited by 768
Acute Coagulopathy of Trauma: Hypoperfusion Induces Systemic Anticoagulation and Hyperfibrinolysis
Brohi, K., Cohen, M. J., Ganter, M. T., Schultz, M. J., Levi, M., Mackersie, R. C., & Pittet, J.-F. (2008) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e318169cd3c · Cited by 733
Murray, C. J. L., & López, A. D. (1996) · Cited by 474
Treatment of traumatic bleeding with recombinant factor VIIa
Kenet, G., Walden, R., Eldad, A., & Martinowitz, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05155-7 · Cited by 458
Macroeconomics and Health: Investing in Health for Economic Development
Ivinson, A. J. (2002) · Nature Medicine · doi:10.1038/nm0602-551b · Cited by 436
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Henry, D. A., Carless, P. A., Moxey, A. J., O'Connell, D., Stokes, B. J., Fergusson, D. A., & Ker, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001886.pub3 · Cited by 398
Shakur, H., Elbourne, D., Gülmezoglu, M., Alfirevic, Z., Ronsmans, C., Allen, E., & Roberts, I. (2010) · Trials · doi:10.1186/1745-6215-11-40 · Cited by 332
Self-citationThe Dose-Response Relationship of Tranexamic Acid
Horrow, J. C., Van Riper, D. F., Strong, M. D., Grunewald, K. E., & Parmet, J. L. (1995) · Anesthesiology · doi:10.1097/00000542-199502000-00009 · Cited by 300
Transfusion medicine: looking to the future
Goodnough, L. T., Shander, A., & Brecher, M. E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12195-2 · Cited by 291
Equity dimensions of road traffic injuries in low- and middle-income countries
Nantulya, V. M., & Reich, M. R. (2003) · Injury Control and Safety Promotion · doi:10.1076/icsp.10.1.13.14116 · Cited by 260
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Henry, D. A., Carless, P. A., Moxey, A. J., O'Connell, D., Stokes, B. J., McClelland, B., Laupacis, A., & Fergusson, D. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001886.pub2 · Cited by 256
Peto, R., & Baigent, C. (1998) · BMJ · doi:10.1136/bmj.317.7167.1170 · Cited by 243
Edwards, P., Roberts, I., Green, J., & Lutchmun, S. (2006) · BMJ · doi:10.1136/bmj.38875.757488.4f · Cited by 194
Self-citationSawamura, A., Hayakawa, M., Gando, S., Kubota, N., Sugano, M., Wada, T., & Katabami, K.-I. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2009.06.034 · Cited by 185
Specific barriers to the conduct of randomized trials
Duley, L., Antman, K., Arena, J., Avezum, A., Blumenthal, M., Bosch, J., Chrolavicius, S., Li, T., Ounpuu, S., Perez, A. C., et al. (2008) · Clinical Trials · doi:10.1177/1740774507087704 · Cited by 176
Plasma Tranexamic Acid Concentrations During Cardiopulmonary Bypass
Fiechtner, B. K., Nuttall, G. A., Johnson, M. E., Dong, Y., Sujirattanawimol, N., Oliver, W. C., Sarpal, R. S., Oyen, L. J., & Ereth, M. H. (2001) · Anesthesia & Analgesia · doi:10.1097/00000539-200105000-00010 · Cited by 166
Medicines for human use (clinical trials) regulations 2004.
(2004) · PubMed · Cited by 161
Perel, P., Salman, R. A., Kawahara, T., Morris, Z., Prieto‐Merino, D., Roberts, I., Sandercock, P. A., Shakur‐Still, H., & Wardlaw, J. M. (2012) · Health Technology Assessment · doi:10.3310/hta16130 · Cited by 153
Self-citationPurchasing power parities (PPP)
(2014) · doi:10.1787/1290ee5a-en · Cited by 143
Anti-fibrinolytic agents in post partum haemorrhage: a systematic review
Ferrer, P., Roberts, I., Sydenham, E., Blackhall, K., & Shakur‐Still, H. (2009) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-9-29 · Cited by 120
Self-citationAntifibrinolytic Therapy in Surgery for Congenital Heart Disease
Eaton, M. P. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181679555 · Cited by 103
Rodgers, A. J., & MacMahon, S. W. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653746 · Cited by 72
Subaiya, S., Hogg, E., & Roberts, I. (2011) · Trials · doi:10.1186/1745-6215-12-31 · Cited by 70
Self-citationTowards sustainable clinical trials
Sustainable Trials Study Group (2007) · BMJ · doi:10.1136/bmj.39140.623137.be · Cited by 63
Dziekan, G., Chisholm, D., Johns, B., Rovira, J., & Hutin, Y. J. (2003) · Europe PMC (PubMed Central) · Cited by 61
Kiwanuka, N., Gray, R. H., Serwadda, D., Li, X., Sewankambo, N. K., Kigozi, G., Lutalo, T., Nalugoda, F. K., & Wawer, M. J. (2004) · AIDS · doi:10.1097/00002030-200401230-00032 · Cited by 47
Research in emergency situations: with or without relatives consent
Roberts, I. (2004) · Emergency Medicine Journal · doi:10.1136/emj.2002.004788 · Cited by 41
Self-citation(2000) · Journal of Neurotrauma · doi:10.1089/neu.2000.17.591 · Cited by 41
Regulation of Therapeutic Research is Compromising the Interests of Patients1
Chalmers, I. (2007) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200721060-00004 · Cited by 37
Causes of death following multiple trauma
Tien, H. C. N., Chu, P. T. Y., & Brenneman, F. D. (2004) · Current Orthopaedics · doi:10.1016/j.cuor.2004.04.006 · Cited by 30
Cited by
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
Self-citationSpahn, D. R., Bouillon, B., Cerny, V., Duranteau, J., Filipescu, D., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,269
Self-citationThe systemic immune response to trauma: an overview of pathophysiology and treatment
Lord, J. M., Midwinter, M. J., Chen, Y.-F., Belli, A., Brohi, K., Kovacs, E. J., Koenderman, L., Kubes, P., & Lilford, R. J. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60687-5 · Cited by 846
Moore, E. E., Moore, H. B., Kornblith, L. Z., Neal, M. D., Hoffman, M., Mutch, N. J., Schöchl, H., Hunt, B. J., & Sauaia, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00264-3 · Cited by 823
Self-citationAnderson, D. R., Morgano, G. P., Bennett, C., Dentali, F., Francis, C. W., Garcia, D. A., Kahn, S. R., Rahman, M., Rajasekhar, A., Rogers, F. B., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000975 · Cited by 626
Metadata
- Authors
- Roberts, I., Shakur, H., Coats, T., Hunt, B., Balogun, E., Barnetson, L., Cook, L., Kawahara, T., Perel, P., Prieto-Merino, D., Ramos, M., Cairns, J., & Guerriero, C.
- Venue
- Health Technol Assess
- Published
- 2013-03
- Volume
- 17
- Issue
- 10
- Pages
- 1-79
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W1986837360
- Cited by
- 794
- References
- 44
- FWCI
- 18.04
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.